BR112012033388A2 - compostos para o tratamento de distúrbios e doenças de segmento posterior - Google Patents

compostos para o tratamento de distúrbios e doenças de segmento posterior

Info

Publication number
BR112012033388A2
BR112012033388A2 BR112012033388A BR112012033388A BR112012033388A2 BR 112012033388 A2 BR112012033388 A2 BR 112012033388A2 BR 112012033388 A BR112012033388 A BR 112012033388A BR 112012033388 A BR112012033388 A BR 112012033388A BR 112012033388 A2 BR112012033388 A2 BR 112012033388A2
Authority
BR
Brazil
Prior art keywords
treatment
compounds
diseases
posterior segment
disorders
Prior art date
Application number
BR112012033388A
Other languages
English (en)
Inventor
Carmelo Romano
David P Bingaman
Jesse A May
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012033388A2 publication Critical patent/BR112012033388A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos para o tratamento de distúrbios e doenças de segmento posterior. a presente invenção refere-se ao uso de determinados compostos de ureia para o tratamento de distúrbios retinais associados à angiogênese e/ou neovascularização ocular patológicas que é descrito.
BR112012033388A 2010-07-02 2011-06-24 compostos para o tratamento de distúrbios e doenças de segmento posterior BR112012033388A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36100310P 2010-07-02 2010-07-02
PCT/US2011/041784 WO2012003141A1 (en) 2010-07-02 2011-06-24 Compounds for the treatment of posterior segment disorders and diseases

Publications (1)

Publication Number Publication Date
BR112012033388A2 true BR112012033388A2 (pt) 2016-11-22

Family

ID=44543755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033388A BR112012033388A2 (pt) 2010-07-02 2011-06-24 compostos para o tratamento de distúrbios e doenças de segmento posterior

Country Status (13)

Country Link
US (1) US20120004245A1 (pt)
EP (1) EP2588098A1 (pt)
JP (1) JP2013530230A (pt)
KR (1) KR20130102524A (pt)
CN (1) CN102985084A (pt)
AR (1) AR082077A1 (pt)
AU (1) AU2011271518A1 (pt)
BR (1) BR112012033388A2 (pt)
CA (1) CA2799587A1 (pt)
MX (1) MX2012014487A (pt)
TW (1) TW201206929A (pt)
UY (1) UY33481A (pt)
WO (1) WO2012003141A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
WO2014002051A2 (en) * 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
JP6214647B2 (ja) * 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002059A1 (en) * 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
US9550755B2 (en) * 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
KR102277833B1 (ko) 2013-02-20 2021-07-14 칼라 파마슈티컬스, 인크. 치료 화합물 및 그의 용도
US9539139B2 (en) 2013-05-03 2017-01-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
CA2914815A1 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US10174022B2 (en) 2014-12-10 2019-01-08 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181468A1 (en) * 2002-03-21 2003-09-25 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20050026944A1 (en) 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20050020619A1 (en) 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006050109A2 (en) 2004-10-29 2006-05-11 Abbott Laboratories Novel kinase inhibitors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070060887A1 (en) 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector

Also Published As

Publication number Publication date
US20120004245A1 (en) 2012-01-05
AU2011271518A1 (en) 2012-12-13
KR20130102524A (ko) 2013-09-17
CN102985084A (zh) 2013-03-20
WO2012003141A1 (en) 2012-01-05
EP2588098A1 (en) 2013-05-08
TW201206929A (en) 2012-02-16
CA2799587A1 (en) 2012-01-05
AR082077A1 (es) 2012-11-07
MX2012014487A (es) 2013-02-21
UY33481A (es) 2011-10-31
JP2013530230A (ja) 2013-07-25

Similar Documents

Publication Publication Date Title
BR112012033388A2 (pt) compostos para o tratamento de distúrbios e doenças de segmento posterior
BR112014012230A2 (pt) fralda de vestir descartável de tamanho pequeno
AR111208A1 (es) ANTICUERPOS ANTI-PÉPTIDO b AMILOIDE N3PGLU Y SUS USOS
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BRPI1013377A2 (pt) formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
BR112016027136A2 (pt) Válvula protética para tratamento de doenças que causam refluxo afetando os membros inferiores
MY164579A (en) Safe and functional humanized antibodies
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
GT201400242A (es) &#34;nuevos compuestos de pirazol&#34;
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
CR20120247A (es) Canfenos arilados novedosos, procesos para su preparación y usos
BR112014032682A2 (pt) anticorpo monoclonal humano contra a proteína vp1 do vírus jc
BR112013004721A2 (pt) &#34;quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3&#34;
BR112014011223A2 (pt) método de tratar uma doença proliferativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]